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We thank Angela Gentile and her co-authors for their insightful
review of disease burden and related immunization policy in their
respective countries.1 Haemophilus inﬂuenzae type b (Hib) disease
causes over 370 000 childhood deaths each year and remains a
signiﬁcant cause of bacterial illness in unvaccinated children.2
Where used routinely in low- and high-income settings alike, Hib
vaccine has virtually eliminated invasive Hib disease.3,4 Inclusion
of Hib vaccines in national EPI (Extended Program on Immuniza-
tion) programs constitutes an important step towards Millennium
Development Goal 4 – reducing childhoodmortality by two-thirds
by 2015.
To help accelerate the national adoption of Hib-containing
vaccines, the GAVI Alliance created the Hib Initiative in 2005 to
support evidence-informed decision-making in 72 low-income
countries. We are heartened by the recent surge in decisions in
these countries to include Hib vaccine in their national EPI
programs. As of June 30, 2009, 66 of 72 GAVI-eligible countries had
made a decision to include Hib-containing vaccine in their national
immunization program. Of these, 55 have already introduced the
vaccine, including Bangladesh and Pakistan, which are included in
the Review, as well as other countries with high disease burdens
like the Democratic Republic of the Congo. Globally, 149 (77%) of
193 World Health Organization (WHO) member states are
currently using Hib vaccine, reaching 56 million of the world’s
children.
Despite this good news, children remain unvaccinated around
the world. As the authors correctly identify, the majority of
children without access to Hib vaccines now live in middle-
income countries, including the authors’ homes (Egypt, Iran, and
Thailand). Even where Hib vaccine is included in the EPI program,
theremay still be challenges to ensure adequate vaccine coverage
in certain parts of these countries. Strengthening health systems
to improve the delivery of immunizations is an urgent priority,DOI of original article: 10.1016/j.ijid.2009.11.006
1201-9712/$36.00 – see front matter  2010 Published by Elsevier Ltd on behalf of In
doi:10.1016/j.ijid.2009.11.014and one that GAVI, the WHO, UNICEF and other partners are
committed to.
Finally, the authors identify the systemic difﬁculties in
detecting disease. This issue is not restricted to the Hib bacterium
alone, and other newer vaccines, including pneumococcal and
rotavirus vaccines, will need to demonstrate national and regional
disease burden to inform policy. Regional evidence and statistical
models (i.e., the Global Burden of Disease project) are feasible and
cost-effective alternatives to traditional research and surveillance
methods. We applaud the efforts of decision-makers to include
life-saving vaccines in their countries’ public health programs, and
we hope that this momentum can be sustained for other new and
underused vaccines.
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